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Background: z-Guggulsterone (z-Gug) and Gugulipid (GL) have been used to treat a variety of ailments. We now
report their anti-cancer effect and mechanism against human breast cancer.
Methods: Using the human estrogen receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer
cells as well as the normal human mammary epithelial cell line (HMEC), we evaluated the anti-breast-cancer efficacy
and apoptosis inducing activity of GL. We determined the cellular and molecular mechanism of GL-inhibited breast
cancer cell growth.
Results: GL significantly inhibited growth of MCF-7 and MDA-MB-231 cells with an IC50~2 μM at pharmacologically
relevant concentrations standardized to its major active constituent z-Gug. The GL-induced growth inhibition
correlated with apoptosis induction as evidenced by an increase in cytoplasmic histone-associated DNA
fragmentation and caspase 3 activity. The GL-induced apoptosis was associated with down-regulation of the
β-Catenin signaling pathway. The decreased expression of Wnt/β-Catenin targeting genes, such as cyclin D1, C-myc
and survivin, and the inhibition of the activity of the transcription factor (T-cell factor 4, TCF-4) were observed in
GL-treated breast cancer cells. The GL treatment resulted in a significant reduction of β-Catenin /TCF-4 complex in
both of the cancer cells. The GL-induced apoptotic cell death was significantly enhanced by RNA Interference of
β-Catenin and TCF-4. On the other hand, the normal human mammary epithelial cell HMEC, compared with the
human breast cancer cells, is significantly more resistant to growth inhibition and apoptosis induction by GL.
Conclusion: The present study indicates that the β-Catenin signaling pathway is the target for GL-induced growth
inhibition and apoptosis in human breast cancer.
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reproduction in any medium, provided the orand worldwide [1]. The clinical utility of ER antagonists
is often limited by side effects [1]. Thus, the identifica-
tion of novel agents that can suppress growth of both
ER-positive and ER-negative human breast cancers and
are still relatively safe is highly desirable.
Gugulipid (GL, guggul, guggal, or gugul lipid) is the
ethyl acetate extract of the gum guggul resin (raw mater-
ial) harvested directly from the Commiphora mukul tree
(family name: Burseraceae; synonyms: Hook, Bandari,
Balsamodendron mukul, and Commiphora Wightii). GL
is a highly valued botanical medicine that has been safely
used for thousands of years in the Indian Ayurvedictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lipid disorders, rheumatoid arthritis, ulcers, osteoarth-
ritis, bone fractures, epilepsy and obesity [2-10]. In
1986, GL was granted approval in India for marketing
as a lipid-lowering drug (Indian Pharmacopeia 2007:
pgs. 2038–2040). Several products of standardized for-
mulations of Commiphora mukul are already in hu-
man use as cholesterol-lowering agents [5-8]. The z-
and E-forms of guggulsterone (Gug, 4,17 [11]-
pregnadie-3, 16-dione) have been identified as major ac-
tive components of GL [2-10]. Numerous studies suggest
that many edible phytochemicals have cancer chemopre-
ventive and chemotherapeutic potential [12]. The evi-
dences of the anti-cancer activity of Gugs were provided
by us and other laboratories [11,13-24]. We were the first
to investigate the inhibitory effect of Gug on the growth of
the human prostate cancer cells [13-16]. The results have
shown that z-Gug significantly inhibits the proliferation of
PC-3, LNCaP and DU145 human prostate cancer cells,
but not that of the normal human prostate epithelial cell
line PrEC [14-16]. Based on these data, we hypothesized
that GL might be more effective in the growth inhibition
of prostate cancer cells because it contains a number of
steroids, including the two isomers z- and E-Gugs. There-
fore, we investigated the anti-cancer potential of GL in hu-
man prostate cancer cells [13]. Our data were the first to
show that GL has a stronger anti-cancer potential in hu-
man prostate cancer cells than z-Gug, one of its active
constituents, as evidenced by greater inhibition of cell
growth [13]. It is reported that treatment with GL (3 μmol
standardized to z-Gug, daily for 3 weeks) resulted in the
enhancement of cetuximab activity in the xenograft model
of head and neck cancer [20]. The Gugs-mediated sup-
pression of cancer cell proliferation has also been reported
in head and neck cancer cells [20], leukemia cells [11,22],
lung cancer cells [22], human breast cancer cells [19], skin
cancer cells [21], and colon cancer cells [23]. Gug treat-
ment inhibited angiogenesis in vitro and in vivo to block
prostate and colon cancer growth [14,23]. In our present
studies, we were the first to report the anti-cancer effect
and mechanism of GL on human breast cancer cells.
Methods
Reagents
Derived from the gum guggul resin (gum guggul) in the
soft bark ducts of the Commiphora mukul tree, GL
is a registered product of Sabinsa Corporation (East
Windsor, NJ, USA, Registration date: July 21, 1992; US
Patent# 6436991 B1). We previously described a manu-
facturing flow chart for the production of GL from gum
guggul resin [2]. The standardization of GL was per-
formed by high-performance liquid chromatography
(HPLC, 2). GL contains ~3.75% z-Gug and is standard-
ized to z-Gug (μM) [2]. The GL was stored at 4°C andfound to be stable for at least 6months. The z-Gug was
from Steraloids (Newport, RI, USA). The reagents for
cell culture including medium, penicillin and strepto-
mycin antibiotic mixture, and fetal bovine serum were
purchased from Invitrogen (Carlsbad, CA, USA). The
ELISA kit for the quantitation of cytoplasmic histone-
associated DNA fragmentation was from Roche Diagnos-
tics (Mannheim, Germany). The intracellular staining/
conjugated cleaved caspase-3 (Asp175) antibody (Alexa
Fluor®488 conjugate) for the determination of caspase
3 activity by Flow cytometry was from cell Signaling
(Danvers, MA, USA). The SurveyorTM IC Human
total β-Catenin Immunoassay kit was from R&D Sys-
tems (Minneapolis, MN, USA). The anti-β-Catenin anti-
body was from Invitrogen, the antibodies against Cyclin
D1, C-Myc, poly-(ADP-ribose)-polymerase (PARP) and
TCF-4 were from Santa Cruz Biotechnology (Dallas, TX,
USA), the antibody against Survivin was from Novus Bio-
logicals, the antibody against α-Tubulin was from Sigma,
and the anti-actin antibody was from Oncogene Research
Products (San Diego, CA, USA). The general caspase in-
hibitor Z-VAD(oMe)-FMK (Z-VAD) was from Enzyme
Systems (Dublin, CA, USA).
Cell culture and cell survival assays
The MDA-MB-231 and MCF-7 cell lines were pur-
chased from the American Type Culture Collection
(Manassas, VA, USA) and maintained by following the
supplier’s recommendations. The normal human mam-
mary epithelial cell line (HMEC) was procured from
Lonza (Walkersville, MD, USA) and cultured in the epi-
thelial cell basal medium (Lonza). Each cell line was
maintained at 37C in an atmosphere of 95% air and 5%
CO2. Stock solution of GL and z-Gug were prepared in
DMSO and an equal volume of DMSO (final concentra-
tion 0.1%) was added to the controls. The effect of GL
and z-Gug on cell viability was determined by the colono-
genic survival assay and trypan blue dye exclusion assays
as described by us previously [13,25]. For the colonogenic
survival assay, cells (1.5×105) were plated in 6-well-plates
for incubation overnight and were then treated with 0.1%
DMSO (control group) or 1, 2.5 and 5 μM GL for 24 h.
The treated cells were re-seeded in 6-well plates (500
cells/well) in complete medium without the drug. The
medium were changed every two days. After culturing for
12days, the cells were fixed and stained with 0.5% crystal
violet in 20% MeOH for colony counting.
Detection of apoptosis
Apoptosis induction by GL was assessed by the analysis
of cytoplasmic histone-associated DNA fragmentation,
which has emerged as a highly sensitive and reliable
technique for the quantitation of apoptotic cell death.
The cytoplasmic histone-associated DNA fragmentation
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In some experiments, cells were pretreated with 40 μM
pan-caspase inhibitor Z-VAD for 2hours before GL
treatment and assessment of apoptotic cell death de-
scribed as our previous study [16].
Determination of caspase-3 activation [13,28]
The activation of caspase-3 was determined by flow cy-
tometry using a kit from Cell Signaling Technology.
Briefly, the cells (3×105) were plated in T25 flasks and
allowed to attach by overnight incubation. The cells
were then treated with Me2SO (control) or the desired
concentrations of GL for the specified time periods. Sub-
sequently, the cells were collected by trypsinization and
processed for the flow cytometric analysis of caspase-3
activation according to the manufacturer’s instructions.
Measurement of β-Catenin level
Experiments to determine the effects of GL on β-catenin
level were carried out using the Surveyor™ IC Human
total β-Catenin Immunoassay kit (R&D Systems) follow-
ing the manufacturer’s instructions. In brief, the cells
(2×106) were seeded in 75 cm2 flasks and allowed to at-
tach by overnight incubation. The cells were treated with
DMSO (control) or 2.5 and 5 μM GL or 20 and 40 μM
z-Gug for 24 h. The cells were collected, washed with
phosphate-buffered saline, and lysed by the specific lysis
buffer provided by the kit. The lysate were used to deter-
mine the β-Catenin level.
Preparation of cell extracts
Whole cell extracts, nuclear extracts (Nuc), and cytosolic
extracts (Cyto) were prepared essentially as described by
us previously [28]. NE-PER® nuclear and cytoplasmic ex-
traction reagents (Pierce product) were used to prepare
cytosolic and nuclear extracts. Briefly, the treated cells
were placed on ice, the medium was removed, and the
cells were washed once with cold PBS. The cells were
then scraped off the dish and collected by centrifugation.
Cell pellets were used to prepare the cytosolic and nu-
clear extracts following the product instructions. The
protein concentration was determined using the Bio-Rad
Protein Assay reagent with bovine serum albumin as the
standard.
Immunoblotting
The lysate proteins were resolved by 6–12.5% sodium
dodecyl sulfate polyacrylamide gel electrophoresis and
transferred onto the membrane. Immunoblotting was
performed as described by us previously [26-28]. The
blots were stripped and re-probed with the anti-actin
antibody to correct for differences in protein loading.
Change in the protein level was determined by densito-
metric scanning of the immunoreactive band andcorrected for actin loading control. Immunoblotting for
each protein was performed at least twice using inde-
pendently prepared lysate proteins.
RNA interference of β-catenin and TCF-4
The cells (1×105) were seeded in six-well plates and
allowed to attach by overnight incubation. The cells were
transfected with 200 nM nonspecific control-siRNA
(QIAGEN, Cambridge, MA, USA, sequences: sense: 5’-
UUCUCCGAACGUGUCACGU-3’, antisense: 5’-ACGUG
ACACGUUCGGAGAA-3’) or β-Catenin (sc-44252, Santa
Cruz, Dallas, TX, USA, sequences: sense: 5’-CUCAGUC
CUUCACUCAAGA-3’, antisense: 5’-UCUUGAGUGAAG
GACUGAG-3’) or TCF-4 (sc-43525, Santa Cruz, Dallas,
TX, USA, sequences: sense: 5’-CUGAGUCCUUCACUC
AAGA-3’, antisense: 5’-UCUUGAGUGAAGGACUGAG-
3’ ) -targeted siRNA using Oligofectamine (Invitrogen,
Grand Island, NY, USA) according to the manu-
facturer’s recommendations. Twenty-four hours after
transfection, the cells were treated with DMSO (con-
trol) or 5 μM GL for specified time period. The cells
were collected, washed with phosphate-buffered saline,
and processed for immunoblotting or analysis of cyto-
plasmic histone-associated DNA fragmentation as de-
scribed previously [26-28].
Immunoprecipitation analyses of the interaction between
β-Catenin and TCF-4 in human breast cancer cells
Aliquots containing 200 μg of total lysate protein from
MCF-7 and MDA-MB-231 cells that were treated with
DMSO (control) or GL were incubated overnight at 4C with
5 μg of anti-β-Catenin antibody. Protein G–agarose beads
(50 μL; Santa Cruz Biotechnology, USA) were then added to
each sample, and the incubation was continued for an add-
itional 2 h at 4C. The immunoprecipitates were washed five
times with lysis buffer and subjected to SDS-PAGE followed
by immunoblotting using anti-TCF-4 antibody.
Statistical analysis
Statistical significance of difference in measured vari-
ables between control and treated groups was deter-
mined by t-test or one-way ANOVA. Difference was
considered significant at P<0.05.
Results
GL inhibited human breast cancer cell growth but not
normal human mammary epithelial cell line HMEC
Initially, the colonogenic assay was used to determine
the effect of GL on cell viability. By following the colony
formation assaying procedure, the cells were cultured
for 12 days after 24 h exposure to GL and the colony
formation (>50 cells/colony) was determined. The viability
of both MCF-7 and MDA-MB-231 cells was decreased
significantly in a concentration-dependent manner with
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within the pharmacologically achievable concentrations
(~3 μM, 25, Figure 1A). To confirm the growth inhibitory
effect of GL, we used the trypan blue dye exclusion assay.
The results indicated that treatment with GL for 24 h
resulted in a significant reduction in cell viability in both
of cancer cells (Figure 1B). Since z-Gug is one of the major
active components of GL, we compared the anti-cancer
activity of GL with that of z-Gug. z-Gug inhibited the hu-
man breast cancer cell growth with an IC50 of GL ~30 μM
(Figure 1C). However, growth inhibitory effect of GL
to the cancer cells was ~10-fold stronger compared
with that of z-Gug (Figure 1). The results indicate that
the anti-cancer effect of GL on breast cancer cells is most
likely attributable to z-Gug as well as other constituent(s).
Interestingly, a normal human mammary epithelial cell
line HMEC was significantly more resistant to growth in-
hibition by GL than were breast cancer cells (Figure 1D).
For instance, 10 μM GL, which inhibited the viability of
MCF-7 and MDA-MB-231 cells by about 90% (Figure 1A-Figure 1 A, Effect of GL (GL contains ~3.75% z-Gug and was standard
cells determined by the colonogenic survival assay. Cells were treated
determinations; bars, SE. *Significantly different (P<0.05) compared with DM
Similar results were observed in two independent experiments. Representa
and z-Gug (C) on survival of MCF-7, MDA-MB-231 and HMEC cells determin
different concentrations of GL or z-Gug for 24 h. Columns, mean of three d
DMSO-treated control by one-way ANOVA followed by Dunnett’s test. Simi
Representative data from a single experiment are shown.B), had minimal effect on HMEC cell viability (Figure 1D).
These data indicated that human breast cancer cells, but
not HMEC, were sensitive to inhibition of cell viability by
GL. Since the MCF-7 and MDA-MB-231 cells exhibited
comparable sensitivity, we also concluded that estrogen
receptor expression does not affect GL-mediated growth
inhibition in human breast cancer cells.
GL inhibits breast cancer cell growth by inducing
apoptotic cell death
To gain further insights into the mechanism of GL-
mediated inhibition of breast cancer cell growth, we de-
termined its effect on cytoplasmic histone-associated
DNA fragmentation, a widely used technique for detec-
tion of apoptosis. The GL treatment resulted in a dose-
dependent increase in cytoplasmic histone-associated
DNA fragmentation in both MCF-7 and MDA-MB-231
cells (Figure 2A). To confirm the results of GL-induced
apoptotic cell death, we further investigated whether GL
treatment increased caspase-3 activity in both cancerized to z-Gug (μM)) on survival of MCF-7 and MDA-MB-231 (A)
with different concentrations of GL for 24 h. Columns, mean of three
SO-treated control by one-way ANOVA followed by Dunnett’s test.
tive data from a single experiment are shown. Effect of GL (B and D)
ed by the trypan blue dye exclusion assay. Cells were treated with
eterminations; bars, SE. *Significantly different (P<0.05) compared with
lar results were observed in two independent experiments.
Figure 2 GL induced apoptosis in MCF-7 and MDA-MB-231 cells, but not in HMEC, determined by (A and D) quantitation of
cytoplasmic histone associated DNA fragmentation, and (B) flow cytomitry analysis of Caspase 3 activity. Cells were treated with the
indicated concentrations of GL or z-Gug (C) or DMSO (control) for 24 hours. Results are expressed as enrichment factor relative to cells treated
with DMSO (control). Results are mean±SE (n=3). *Significantly different (P<0.05) between the indicated groups by one-way ANOVA followed by
by Dunnett’s test. Similar results were observed in at least two independent experiments. Representative data from a single experiment are
shown. Effect of pretreatment with general caspase inhibitor Z-VAD on GL-induced cytoplasmic histone-associated DNA fragmentation (E) and
caspase 3 activity (F) in MCF-7 and MDA-MB-231 cells. Columns, mean (n=3); bars, SE. a, p<0.05, significantly different compared with control; b,
p<0.05, significantly different compared with GL alone treatment group (one-way ANOVA followed by Bonferroni’s test for multiple comparisons).
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was observed in GL-treated MCF-7 and MD-MB-231
cells (Figure 2B). Taken together, these observations
clearly indicated that the antiproliferative effect of GL
against breast cancer cells was associated with apoptosis
induction (Figure 2A-B). Consistent with the cell via-
bility data (Figure 1C), z-Gug at 20 μM can induce apo-
ptosis (cytoplasmic histone-associated DNA fragmen
tation) in both cancer cells (Figure 2C). The same treat-
ment with 2.5 and 5 μM GL to HMEC did not cause anyapoptotic cell death (Figure 2D). The present study indi-
cated that the effect of apoptosis inducing by GL is se-
lective for breast cancer cells but not for normal human
mammary epithelial cell HMEC (Figure 2D).
GL-induced apoptosis is caspase-dependent
Next, we investigated whether the apoptotic cell death
induced by GL is caspase dependence. To determine the
role of caspases, the MCF-7 and MDA-MB-231 cells
were pretreated with pan-caspase inhibitor Z-VAD
Figure 3 GL (A and C) and z-Gug (B) inhibited β-Catenin level
in human breast cancer MCF-7 and MDA-MB-231 cells as well
as HMEC. Cells were treated with DMSO (control) or 2.5 and 5 μmol/L
GL standardized to z-Gug or 20 and 40 μmol/L z-Gug for 24h. β-
Catenin level was determined by using the SurveyorTM IC Human total
β-Catenin Immunoassay kit (R&D Systems) following the manufacturer’s
instructions. Experiments were repeated twice with triplicate
measurements in each experiment. Results are mean±SE (n=3).
*Significantly different (P<0.05) between the indicated groups by one-
way ANOVA followed by Dennett’s test. The results were consistent
and representative data from a single experiment are shown.
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for 24 hours. As shown in Figure 2E-F, the GL-induced
cytoplasmic histone-associated DNA-fragmentation and
Caspase 3 activity in human breast cancer cells were
fully blocked in the presence of Z-VAD. These results
clearly suggest that the GL-induced apoptosis in human
breast cancer cells was mediated by caspases.
GL treatment caused the decrease of β-Catenin level in
breast cancer cells
The Wnt/ β-Catenin signaling pathway plays an im-
portant role in carcinogenesis and tumor metastasis,
which is involved in virtually many cancer types in-
cluding breast cancer [29,30]. Thus, targeting the Wnt/
β-Catenin-TCF signaling is of great significance for
chemoprevention and chemotherapy of cancer. The
previous studies have shown that many natural prod-
ucts [31-35], such as, resveratrol [32], curcumin [33],
cucurbitacin B [34], and lycopene [35] cause apoptosis
through regulation of Wnt/ β-Catenin-TCF signaling.
We tested whether GL-induced apoptosis was involved
in β-Catenin signaling. As shown in Figure 3A, treat-
ment with GL at 2.5 and 5 μM resulted in a dose-
dependent decrease of the β-Catenin levels in human
breast cancer MCF-7 and MDA-MB-231 cells com-
pared with DMSO-treated (control) cells. For example,
the β-Catenin levels in MCF-7 and MDA-MB-231 cells
treated for 24 h with 5 μM GL were decreased by
about 89% and 83%, respectively, as compared to the
levels in the control group (Figure 3A). Significant in-
hibition of β-Catenin levels was also observed in the
same time treatment of z-Gug at 20 and 40 μM in
both cancer cells (Figure 3B). However, the GL-induced
the decrease of the β-Catenin levels could not be observed
in the GL-treated HMEC (Figure 3C). These observations
clearly indicated that GL treatment resulted in the inhib-
ition of β-Catenin signaling production in human breast
cancer cells.
Effect of GL treatment on the protein expression of β-
Catenin and its targeting proteins in breast cancer cells
To confirm the GL-inhibited effect of β-Catenin signaling,
we determined whether GL treatment can regulate the
β-Catenin protein levels. The effect of GL treatment on
levels of β-Catenin protein in human breast cancer MCF-
7 and MDA-MB-231 cells was determined by immunob-
lotting. Representative blots are shown in Figure 4A-B.
The levels of β-Catenin protein were remarkably de-
creased in GL-treated MCF-7 and MDA-MB-231 cells.
For example, MCF-7 cells treated with 5 and 10 μM GL
resulted in a decrease of 30% and 70% for β-Catenin pro-
tein expression respectively, as compared with the con-
trols (Figure 4A). The MDA-MB-231 cells had almost the
same response to GL treatment (Figure 4B). To determine
Figure 4 Immunoblotting for β-Catenin, C-myc, Cyclin D1 and Survival proteins using lysates from MCF-7 (A) or MDA-MB-231 (B) cells
treated with DMSO (control) or 5 and 10 μmol/L GL standardized to z-Gug or 10 and 40 μmol/L z-Gug for 24 h. The blot was stripped
and reprobed with anti-actin antibody to ensure equal protein loading. The numbers on top of the immunoreactive bands represent change in
protein levels relative to corresponding DMSO-treated control. Immunoblotting for β-Catenin protein using isolated cytosolic and nuclear
fractions from MCF-7 (C) or MDA-MB-231 (D) cells following 24-h treatment with DMSO or 5 μmol/L GL or 40 μmol/L z-Gug. The blot was
reprobed with anti-α-Tubulin or anti-PARP antibody to ensure purity of the nuclear fraction. The numbers on top of the immunoreactive bands
represent change in levels relative to DMSO-treated control. Immunoblotting for each protein was performed at least twice using independently
prepared lysates.
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targeting genes, the protein levels of C-myc, Cyclin D1
and survivin were measured by immunobletting. GL treat-
ment resulted in a significant down-regulation of these
gene proteins (Figure 4A-B). In addition, z-Gug could in-
hibit the protein expression of β-Catenin as well as the
protein levels of C-myc, Cyclin D1 and survivin in both
cancer cells (Figure 4A-B). These results indicated that GL
treatment inhibited the β-Catenin and its targeting gene
proteins in human breast cancer cells.
GL inhibited the nuclear translocation of β-Catenin
Since GL treatment down-regulated the β-Catenin sig-
naling pathway in the human breast cancer cells
(Figures 3–4), we hypothesized that GL might also
inhibit translocation of β-Catenin to nuclei. To deter-
mine the β-Catenin protein levels in both the cyto-
plasmic and nuclear fractions, we isolated both fractionsfrom the control cells and the GL- or z-Gug-treated
cells. The expression of β-Catenin protein in the
cytoplasmic and nuclear fractions was measured by
immunoblotting (Figure 4C-D). GL as well as z-Gug
treatments significantly decreased the β-Catenin protein
level of the nuclear fraction in both MCF-7 and MDA-
MB-231 cells (Figure 4C-D). The treatment of 5 μM GL
greatly reduced the level of nuclear β-Catenin in both can-
cer cells. For example, GL down-regulated the nuclear β-
Catenin protein by 80%-90% with respect to the protein
level in the the control cells (Figure 4C-D). These data
suggested that GL inhibited the nuclear translocation of
β-Catenin protein in human breast cancer cells.
GL-induced apoptosis was enhanced by RNA interference
of β-Catenin in breast cancer cells
Next, we used siRNA technology to directly test the
contribution of β-Catenin in the regulation of GL-
Figure 5 Immunoblotting for β-Catenin using lysates from MCF-7 (A) or MDA-MB-231 (C) cells transiently transfected with a control
nonspecific siRNA or β-Catenin -targeted siRNA and treated for 24 h with DMSO or 5 μmol/L GL. The blots were stripped and reprobed
with anti-actin antibody to ensure equal protein loading. The numbers on top of the immunoreactive bands represent changes in protein levels
relative to DMSO-treated nonspecific control siRNA–transfected cells. Cytoplasmic histone-associated apoptotic DNA fragmentation in MCF-7 (B)
or MDA-MB-231 (D) cells transiently transfected with a control nonspecific siRNA or β-Catenin -targeted siRNA and treated for 24 h with DMSO or
5 μmol/L GL. The results are expressed as enrichment factor relative to DMSO-treated control cells transiently transfected with the control
nonspecific siRNA. Each experiment was done twice, and representative data from a single experiment are shown. Columns, mean (n=3); bars, SE.
*, P<0.05, significantly different between the indicated groups by paired t test.
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level of β-Catenin protein was decreased by∼90% by
transient transfection of MCF-7 and MDA-MB-231
cells with β-Catenin-targeted siRNA compared with
cells transfected with a control nonspecific siRNA.
Similar to GL’s effect on untransfected cells (Figure 4A-B),
the GL treatment (5 μmol/L, 24 h) caused a decrease in
levels of β-Catenin in both MCF-7 and MDA-MB-231
cells transfected with the nonspecific control-siRNA
(Figure 5A and C). The GL-mediated reductions of β-
Catenin were markedly enhanced in both MCF-7 and
MDA-MB-231 cells transfected with the β-Catenin -
targeted siRNA (Figure 5A and C). Twenty-four–hour
exposure of nonspecific control-siRNA–transfected
MCF-7 and MDA-MB-231 cells to 5 μM GL resulted in
around 3-fold increase in cytoplasmic histone-associated
DNA fragmentation compared with DMSO-treated control
(Figure 5B and D). A remarkable increase apoptotic cell
death was observed in both β-Catenin-depleted cells
treated with GL compared with cells transfected with
control-siRNA and treated with GL (Figure 5B and D).
Collectively, these results indicated that β-Catenin play an
important role in the GL-induced apoptosis in human
breast cancer cells.GL inhibited the β-Catenin-medicated TCF protein
expression and the knockdown of TCF-4 protein
increased GL-induced apoptotic cell death in human
breast cancer cells
Since β-Catenin is involved in the GL-induced apoptosis, we
questioned whether GL-induced apoptotic cell death is regu-
lated by β-Catenin/TCF signaling. To elucidate the mechan-
ism of GL-induced apoptosis in human breast cancer cells,
we investigated its effect on TCF protein expression. The
MCF-7 (Figure 6A) and MDA-MB-231 (Figure 6B) cells
with 2.5 and 5 μM GL exhibited a reduction of TCF protein
level. In addition, treatment of 40 μM z-Gug were found to
down-regulate the expression of TCF protein in both MCF-
7 and MDA-MB-231 cells (Figure 6A-B). These results indi-
cated that the TCF signaling may be involved in GL-induced
apoptosis in human breast cancer cells. Therefore, the role
of the TCF signaling in the apoptosis induction by GL was
determined by using the siRNA technology. As can be seen
from Figure 6C-D, the protein levels of TCF were nearly
knocked down in both MCF-7 and MDA-MB-231 cells by
transient transfection with TCF-4-targeted siRNA when
compared with cells transfected with a nonspecific control-
siRNA. Furthermore, exposure to GL 5 μM for 24 h
resulted in statistically significant increase in cytoplasmic
Figure 6 Immunoblotting for TCF-4 using lysates from MCF-7 (A) or MDA-MB-231 (B) cells treated with DMSO (control) or 5 μmol/L GL
for 24 h. Immunoblotting for TCF-4 using lysates from MCF-7 (C) or MDA-MB-231 (D) cells transiently transfected with a control nonspecific
siRNA or TCF-4 -targeted siRNA and treated for 24 h with DMSO or 5 μmol/L GL. The blots were stripped and reprobed with anti-actin antibody
to ensure equal protein loading. The numbers on top of the immunoreactive bands represent changes in protein levels relative to DMSO-treated
control cells (A-B) or relative to DMSO-treated nonspecific control siRNA–transfected cells (C-D). Cytoplasmic histone-associated apoptotic DNA
fragmentation in MCF-7 (E) or MDA-MB-231 (F) cells transiently transfected with a control nonspecific siRNA or TCF-4-targeted siRNA and treated
for 24 h with DMSO or 5 μmol/L GL. The results are expressed as enrichment factor relative to DMSO-treated control cells transiently transfected
with the control nonspecific siRNA. Each experiment was done twice, and representative data from a single experiment are shown. Columns,
mean (n=3); bars, SE. *, P<0.05, significantly different between the indicated groups by paired t test. GL treatment inhibited β-Catenin binding to
TCF in human breast cancer cells. Immunoblotting for TCF-4 using β-Catenin immunoprecipitates from MCF-7 (H) and MDA-MB-231 (G) cells
treated for 24 h with DMSO (control) or GL 2.5 and 5 μM. The numbers on top of the immunoreactive bands represent change in levels relative
to DMSO-treated control for each cell line. Each experiment was performed at least twice using independently prepared lysates.
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control) in the control-siRNA transfected MCF-7 and
MDA-MB-231 cells, but resulted significantly greater in-
crease (around 6 fold of control) in the cells transiently
transfected with the TCF-4-siRNA (Figure 6E-F). The data
indicated that the GL-induced apoptosis is mediated by β-
Catenin/TCF signaling pathways.GL inhibited the binding of β-Catenin to TCF-4 in human
breast cancer cells
Previous studies have shown that nuclear β-Catenin
complexes with TCF-4 and disruption of this interaction
are necessary for the inhibition of β-Catenin/TCF-4 sig-
naling pathway [31,32]. Therefore, we tested the possibi-
lity of whether GL treatment affected the interaction
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the β-Catenin-TCF-4 complex was detectable in DMSO-
treated (control) MCF-7 and MDA-MB-231 cells as
evidenced by immunoprecipitation using the anti- β-
Catenin antibody followed by immunoblotting with the
anti-TCF-4 antibody. The level of β-Catenin-TCF-4 com-
plex was decreased by ∼95% in MCF-7 and MDA-MB-231
cells treated with 2.5 and 5 μM GL for 24 h when com-
pared with that of the DMSO-treated cells (Figure 6G-H).
These results showed that GL treatment disrupted the
interaction between β-Catenin and TCF-4 in human
breast cancer cells.
Discussion
GL has recently been the focus of attention for its che-
mopreventive and chemotherapeutic potential for cancer
[10-24]. Although the mechanisms of the anti-cancer ac-
tion of GL are not completely understood, these studies,
including ours, have indeed indicated that GL and its ac-
tive components (Gugs) inhibit cancer cell viability by
causing apoptosis [10-24]. The mechanisms underlying
GL-induced apoptosis are involved in the change of Bcl-
2 gene family proteins [10,12-17], the inhibition of NF-
kB signaling [17-19,22], the regulation of MAPK path-
ways [13,15], the suppression of farnesoid X receptor
[5,18] and the bile acid receptor [5,18], and the inhib-
ition of EGFR-STAT3 signaling [20,23]. The results im-
plicated the involvement of the STAT3 and the VEGF/
VEGFR signaling pathways in the regulation of GL-
mediated anti-angiogenesis activity [14,23]. In the pre-
sent study, we, for the first time, showed that GL treat-
ment significantly inhibited the human breast cancer cell
growth and caused apoptotic cell death. Our results re-
vealed a novel anti-cancer mechanism of GL, in which
the β-Catenin signaling pathway is involved in the GL-
induced apoptosis in human breast cancer.
Our data indicate that GL has a stronger anti-cancer po-
tential in human breast cancer cells than one of its active
constituents (z-Gug) as evidenced by their differences in
the inhibition of cell growth and the induction of apop-
totic cell death. The inhibition of cell survival by GL was
Statistically significant as evidenced by IC50~2 μmol/L con-
centrations standardized to z-Gug. The growth inhibition
by GL was ~10-fold stronger compared with that of z-Gug
(Figure 1). although pharmacokinetic parameters for GL
have not been determined in humans, the maximal plasma
concentration of z-Gug (Cmax) in rats was shown to be
3.3- and 18.3 μmol/L following oral gavage with 50 mg
z-Gug/Kg body weight and intravenous injection with
18 mg z-Gug/Kg body weight, respectively [25]. Based on
these pharmacokinetic observations, it is possible that the
concentrations of GL needed to inhibit cancer cell growth
may be achievable in humans. Our previous results have
shown that a normal prostate epithelial cell line PrEC wassignificantly more resistant to growth inhibition by GL or
z-Gug compared with prostate cancer cells. Therefore, we
investigated whether GL treatment has a selective activity
to human breast cancer calls and human normal mammary
epithelial cells by conducting experiments on the effects of
GL on the proliferation and apoptosis inducing of HMEC,
a normal human mammary epithelial cell line. The data
clearly showed that GL-treated HMEC cells displayed a
relatively significantly less cell growth inhibition than the
GL-treated human breast cancer cell (Figure 1). Based on
these results, we conclude that (a) uncharacterized con-
stituent(s) of GL may interact additively or synergistically to
inhibit the viability of human breast cancer cells, (b) a nor-
mal human mammary epithelial cell line is significantly
more resistant to the growth inhibition by GL, and (c) the
growth inhibition of human breast cancer cells by GL is
not influenced by the estrogen receptor expression.
The present results clearly indicated that anticancer
activity of GL against human breast cancer cells is asso-
ciated with apoptosis induction. The conclusion is based
on the following: (a) GL treatment caused a significant
increase of cytoplasmic histone-associated DNA frag-
mentation in human breast cancer cells (Figure 2A), (b)
an increase of caspase 3 activity was observed in GL-
treated breast cancer cells (Figure 2B), and (c) the same
GL treatment could not induce apoptosis in the normal
human mammary epithelial cell HMEC (Figure 2D).
The Wnt/β-Catenin signaling is involved in the devel-
opment and disease including cancer [29,30,36]. Dere-
gulation of the Wnt/β-Catenin signaling has been im
plicated in the pathogenesis of many kinds of human
cancers including breast cancer [29-31,34-36]. Since β-
Catenin plays a key role in the Wnt signaling pathway
[29,36], the disruption of Wnt/β-Catenin signaling rep-
resents a great opportunity to develop novel drugs for
cancer chemoprevention and therapy [31-37]. Some nat-
ural products have shown the potential for the inhibition
of cancer growth through the inactivation of the Wnt/β-
Catenin signaling [31-37]. For example, resveratrol was
capable of disrupting the binding between β-Catenin
and TCF-4, but not affect the accumulation and nuclear
targeting of β-Catenin signaling [32]. The molecular
mechanism of curcumin for the anticancer action is in-
volved in the inhibition of nuclear β-Catenin transcrip-
tion activity and the enhancement of the levels of
membrane β-Catenin via the activation of PKD1 [33].
Cucurbitacin B induced apoptosis and caused the growth
inhibition of breast cancer cells through the reduction of
the Wnt-associated proteins and the inhibition of GSK-3
β-mediated β-Catenin to the nucleus [34]. Lycopene syn-
ergistically enhanced quinacrine anticancer action and
inhibited the β-Catenin signaling is dependent to APC
[35]. Our present results indeed suggest that the β-
Catenin signaling pathway is involved in the GL-induced
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cing. First of all, the β-Catenin levels were significantly
reduced in GL-treated human breast cancer MCF-7 and
MDA-MB-231 cells compared to DMSO-treated control
cells (Figure 3). The data were confirmed by the immun-
blotting results that showed the GL treatment resulted
in a dose-dependent down-regulation of the β-Catenin
protein expression in both cancer cells (Figure 4A-B).
Furthermore, a significant inhibition of the nuclear trans-
location of β-Catenin was observed in both cancer cells
that were treated with 5 μM GL and 40 μM z-Gug
(Figure 5C-D). To determine the real role of β-Catenin in
the GL-induced apoptotic cell death in our models, we
knocked-down β-Catenin in the cells by β-Catenin-siRNA
and then measured the β-Catenin protein expression and
apoptosis induction. The present data showed that the
GL-induced down-regulation of β-Catenin and apoptosis
were significantly enhanced by the siRNA knock-
down in the both cancer cells (Figure 5). Taken to-
gether, these results indicated that β-Catenin is the
real target for the GL-induced apoptosis in human
breast cancer cells.
The Wnt/β-Catenin signaling plays an important role
in breast cancer initiation, progression and metastasis
[30,38-41]. The activation status of Wnt/ β-Catenin sig-
naling has been reported in human breast cancer
[29,30,38-41]. β-Catenin has a central role in Wnt sig-
naling pathway via effects on the TCF-mediated tran-
scription [29-31]. The abnormal β-Catenin levels could
enhance the β-Catenin binding to TCF [29-31,38-41].
We hypothesized that the apoptosis response to GL
may be mediated by TCF-4. Herein, we have provided
the evidence that the GL treatment causes significant
down-regulation of the TCF-4 protein expression in
human breast cancer MCF-7 and MDA-MB-231 cells
(Figure 6A-B). Moreover, the GL-induced apoptotic cell
death as well as the reduction of TCF-4 levels is
significantly enhanced by the knockdown of TCF-4
(Figure 6C-F). Therefore, we conclude that the GL-
induced apoptotic cell death in human breast cancer cells
is regulated by TCF-4. Importantly, our present results
showed that the GL treatment reduced a ∼ 95% of the
complex of β-Catenin/TCF in MCF-7 and MDA-MB-
231 cells, compared with the DMSO-treated control cells
(Figure 6H-G). In conclusion, GL treatment does not only
inhibit the nuclear translocation of β-Catenin and the
TCF-4 protein expression but also disrupts the β-Catenin/
TCF-4 complex in the human breast cancer cells
(Figures 5 and 6). For example, treatment of 5 μM in
MCF-7 and MDA-MB-231 cells down-regulated the β-
Catenin protein expression by 50-60% and the TCF-4 pro-
tein levels by 60-70%, respectively (Figures 4–6). The same
treatment, however, can exert a ∼ 95% inhibition of the β-
Catenin binding to TCF-4 in both cancer cells (Figure 6).A variety of Wnt/ β-Catenin targeting genes have been
identified, including those that regulate cell proliferation
and apoptosis, thus mediating cancer initiation and pro-
gression [29,36]. TCF-4 binds to β-Catenin to tran-
sactivate Wnt target genes that include oncogenic genes
c-Myc, cyclin D1 and survivin [29-31,38-41]. Interest-
ingly, we found that GL and z-Gug significantly inhibit
the protein expression of Wnt/β-Catenin downstream
effectors c-Myc, cyclin D1 and survivin in both breast
cancer cells (Figure 4A-B).
Conclusion
We, for the first time, reported that GL is a potent in-
hibitor of breast cancer cell growth. The present study
reveals a novel mechanism of GL-anticancer activity.
The GL-induced apoptotic cell death in human breast
cancer is regulated by the β-Catenin signaling pathway.
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